Abstracts tagged "comparative effectiveness"

Abstract Number: 2022 • ACR Convergence 2024
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Sharan Rai¹, Gregory Challener¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Chio Yokose¹, saiajay chigurupati², Bohang Jiang², Kiara Tan², Natalie McCormick² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
Abstract Number: 2075 • ACR Convergence 2024
A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD)
Saadia Sasha Ali¹, Alexandra Lawrence², Katie Bechman³, Amit Patel⁴, Surinder biring³, Sophia Steer⁴, Arti Mahto⁵, Catherine Myall⁴, Louise Pollard⁶, Marium Naqvi⁴, Amelia Holloway⁴, Rosaria Salerno⁴, Flora Dell'accio⁴, Sangita Agarwal⁷, Boris Lams⁸, Alex West⁷ and Patrick Gordon⁹, ¹King's College Hospital, Epsom, United Kingdom, ²Guys and St Thomas's Hospital, London, United Kingdom, ³King's College London, London, United Kingdom, ⁴King's College Hospital, London, United Kingdom, ⁵King's College Hospital, London, United Kingdom, ⁶University Hospital Lewisham, London, United Kingdom, ⁷Guy's and St Thomas' Hopsital, London, United Kingdom, ⁸Guys and St Thomas' Hospital, London, ⁹nhs, London, United Kingdom
Background/Purpose: ILD is associated with poor survival in patients with idiopathic inflammatory myopathies (IIM). Cyclophosphamide is often used in the management of myositis associated ILD…
Abstract Number: 2164 • ACR Convergence 2024
Boosting Adherence to “Sick Day Rules”: A Quality Improvement Study in Rheumatology Outpatients on Immunosuppressive Medications, Results of Post-intervention Phase
Merve Aksoy*, Pamela Gonzalez Manrique, Heinrich-Karl Greenblatt and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI
Background/Purpose: Acute infections are common among rheumatology outpatients receiving immunosuppressive medications (IS). Expert guidance advises pausing IS during acute infection, resuming only when clinically improved,…
Abstract Number: 2394 • ACR Convergence 2024
Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis
Diana Gavilanes¹, Alex Jakubiak², Jhon. F Martinez³ and Anas Atrash⁴, ¹UPMC Health Plan - Harrisburg Pa, Harrisburg, PA, ²Drexel University, Philadelphia, PA, ³BaylorScott&White Health, Waco, TX, ⁴UPMC Health Plan - Harrisburg Pa, Harrisburg, PA
Background/Purpose: Major and moderate surgeries are more common in patients with autoimmune diseases. However, there is limited data available regarding the use of standard doses…
Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
April Jorge¹, Aakash Patel¹, Baijun Zhou², Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
Abstract Number: 0250 • ACR Convergence 2024
Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies
Beiming Wang¹, Shi Chen², Xiaoqing Liu³ and Lifan Zhang³, ¹Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking union medical college hospital, Beijing, China
Background/Purpose: As patients with rheumatic diseases (RDs) growing into a large population globally, concerns continue exist regarding the potential development of tuberculosis (TB) in this…
Abstract Number: 0501 • ACR Convergence 2024
How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)
Delphine Sophie Courvoisier¹, Yacine Mrad¹, Denis Mongin¹, Romain Aymon², Roberto Caporali³, Denis Choquette⁴, Catalin Codreanu⁵, Louis Coupal⁴, Doreen Huschek⁶, Kimme Hyrich⁷, Florenzo Iannone⁸, Tore K. Kvien⁹, Monika Mustak¹⁰, Dan Nordstrom¹¹, Nina Trokovic¹², Lucia Otero-Varela¹³, Karel Pavelka¹⁴, Manuel Enrique Pombo Suarez¹⁵, Sella A. Provan¹⁶, Ana Maria Rodrigues¹⁷, Ziga Rotar¹⁸, Prodromos Sidiropoulos¹⁹, Anja Strangfeld²⁰, Jakub Závada¹⁴, Sizheng Zhao²¹, Axel Finckh¹ and Kim Lauper¹, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Rhumadata™, Montreal, QC, Canada, ⁵University of Medicine and Pharmacy, Bucharest, Romania, ⁶German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, ⁷Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁸Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹⁵Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ¹⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁷Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁸University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, ²⁰German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, ²¹Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom
Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 0817 • ACR Convergence 2023
Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)
Bedru Abafita¹, Ambrish Singh¹, Dawn Aitken¹, Steffany Moonaz², Andrew J Palmer¹, Leigh Blizzard¹, Changhai Ding¹, Stan Drummen¹, Graeme Jones³, Kim Bennell⁴ and Benny Samuel Antony¹, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Department of Clinical and Health Services Research, Southern California University of Health Sciences, Whittier, CA, ³Menzies Institute for Medical Research, University of Tasmania, Melbourne, Australia, ⁴University of Melbourne, Melbourne, Australia
Background/Purpose: There is uncertainty about the best type of exercise to optimise outcomes for people with knee osteoarthritis (OA). Strengthening exercise is commonly recommended. However,…
Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Sarah Ringold¹, George Tomlinson², Laura Schanberg³, vincent del gaizo⁴, Katherine Murphy⁵, Brian Feldman⁶, Mei-Sing Ong⁷, Marc Natter⁸, Yukiko Kimura⁹ and For The CARRA Registry Investgators⁴, ¹Seattle Children's Hospital, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Duke University School of Medicine, Durham, NC, ⁴CARRA, Inc, Washington, DC, ⁵Non-clinical, New Orleans, LA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ⁸Harvard Medical School, Boston, MA, ⁹Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
Abstract Number: 0973 • ACR Convergence 2023
Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Yeo-Jin Song¹, Jungyong Han², Hye Won Kim³, Eunwoo Nam³, Sang Won Lee⁴, Shin-Seok Lee⁵, Hye-Soon Lee⁶, Sung-Hoon Park⁷, Yeon-Ah Lee⁸, Sung Hae Chang⁹, Min-Chan Park¹⁰, Hyoun-Ah Kim¹¹, Hyun-Sook Kim¹², Bo Young Yoon¹³, Yong-Gil Kim¹⁴, Hae-Rim Kim¹⁵, Jae Hoon Kim¹⁶, Jisoo Lee¹⁷, Jeongim Choi¹⁸, Wan-Sik Uhm¹⁹ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ⁴Hanyang University, Seoul, South Korea, ⁵Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁶Hanyang University, Guri, South Korea, ⁷Daegu Catholic University School of Medicine, Daegu, South Korea, ⁸Kyung Hee University Hospital, Seoul, South Korea, ⁹Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ¹⁰Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ¹¹Ajou University School of Medicine, Suwon, South Korea, ¹²Soonchunhyang University Seoul Hospital, Seoul, South Korea, ¹³Inje University Ilsan Paik Hospital, Goyang, South Korea, ¹⁴Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ¹⁵Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁶Korea University Medical Center, Seoul, South Korea, ¹⁷Ewha Womans Univ College of Medicine, Seoul, South Korea, ¹⁸Busan Saint Mary's Hospital, Busan, South Korea, ¹⁹Uhm's Rheumatism Clinic, Seoul, South Korea
Background/Purpose: Although clinical trials have shown similar effectiveness between Janus kinase inhibitors (JAKi) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), the choice between these two options…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 1526 • ACR Convergence 2023
Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study
Lisa Kaly¹, mark Volevich¹, shiri keret², Abid Awisat³, Aniela Shouval¹, Itzhak Rosner⁴, Michel Rozenbaum¹, Nina Boulman¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion, Atlit, Israel, ³Bney-Zion Medical Center, Baqa Elgharbiya, Israel, ⁴Bnai Zion Medical Center/Technion, Haifa, Israel
Background/Purpose: B cell depleting therapy (rituximab) and Autologous Hematopoietic Stem Cell transplantation (AHSCT) result in impaired ability to mount a humoral immune response. Evusheld (tixagevimab…
Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Roger Yang¹, Ellen Romich², Shubhasree Banerjee³, Naomi Amudala³, Peter Merkel³, Joshua Baker³ and Rennie Rhee³, ¹University of Pennsylvania, Montréal, QC, Canada, ²Hospital of the University of Pennsylvania, Media, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].